On October 4, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that total 3 innovative clinical Phase II data of Timdarpacept (IMM01), the first SIRPαFc fusion protein targeting human CD47 in China, will be reported at the 2023 American Society of Hematology (ASH) Annual Meeting. Two phase II clinical data summary, for first-line MDS therapy and for cHL indications after PD1 antibody treatment failure will be presented orally, research results of first-line for CMML indication were presented in form of poster.
Founder and Chairman of ImmuneOnco Dr. Tian, Wenzhi said:
"The research results presented at the ASH 2023 conference will provide the latest clinical research data of IMM01. Due to the differentiated design of our drug molecules, IMM01 was shown in in vitro experiments not to bind to red blood cells at all and avoid severe anemia events. At the same time, due to glycosylation modification, the immunogenicity of the drug is greatly reduced, the pharmacokinetic parameters are improved, and the bioavailability of the drug is significantly increased. What is more important is that, among the newly treated Chinese patients, great efficacy and good tolerability were observed in high-risk MDS patients, treatment-naïve CMML patients, treatment-naïve AML patients, and cHL patients after failure of previous PD1 antibody treatment. Among those enrolled patients, multiple complete responses (CR) were observed in various tumor types, which is expected to give patients a chance of long-term survival. We are very pleased to have the opportunity to share these data with colleagues in the field of oncology and look forward to the further release of more clinical data from IMM01.
Chief Medical Officer/Senior Vice President of ImmuneOnco Dr. Lu, Qiying said:
"Following the first ASH poster last year, the three clinical phase II study results of IMM01 have once again been recognized and affirmed by ASH this year. Two articles were accepted by ASH as oral reports and one article was displayed as a poster. IMM01 is the company's key product, those reported phase II results are the important cornerstones of the company in the field of anti-tumor immunotherapy. In terms of clinical development layout of IMM01 products, we have carried out a differentiated strategy. For newly treated CMML patients, IMM01-02 is the largest prospective clinical study with the largest sample size for the rare tumor with unmet medical needs. For the unmet medical need of cHL after previous PD1 failure, our combination treatment model is expected to overcome the resistance to PD1 antibody treatments and embodies the advantages of chemotherapy-free which can avoid the long-term toxicity caused by chemotherapy and bring long-term better quality of life to patients. Exciting efficacy and good tolerability were observed in intermediate to high-risk treatment-naïve MDS, treatment-naïve CMML patients, and cHL patients after PD1 antibody treatment failure. We look forward to advancing rapidly the clinical development of IMM01, bringing new treatment options to tumor patients and solving unmet clinical needs.